Debesh Mandal

2.9K posts

Debesh Mandal banner
Debesh Mandal

Debesh Mandal

@debesh

Co-founder and CEO @nanograb (YC S23)

London Katılım Ocak 2012
1.6K Takip Edilen419 Takipçiler
Debesh Mandal retweetledi
Yair Einhorn
Yair Einhorn@yaireinhorn·
This excellent @Citeline 📊👇shows the exponential rise in the Gene & Cell Therapy field over the past 30 years. 2026 continues show strength with 2,115 Gene Therapies currently being developed to cure genetic diseases & 2,610 Cell therapies in different R&D stages. #ASGCT2026
Yair Einhorn tweet media
English
2
7
15
1.9K
Debesh Mandal
Debesh Mandal@debesh·
solving ai for bio means ultimate competitive thought dynamics across multiple disciplines we see this in our company where ai, physics, chemistry, bio and bd all have to work together simultaneously
English
0
0
2
43
Patrick Collison
Patrick Collison@patrickc·
Which are the most common everyday phenomena that we don't properly understand? Off the top of my head: • Lightning (how does it happen?) • Sleep; dreams (why do they exist?) • Glass (thermodynamics of formation) • Turbulence (when does it start?) • Morphogenesis (how does a creature know what should go where?) • Rain (it seems to start faster than models would predict) • Ice (dynamics of slipperiness) • Static electricity (which material will donate electrons?) • General anaesthetic. (And the mechanism of a lot of drugs, e.g. paracetamol.)
Patrick Collison@patrickc

Some progress in lightning: quantamagazine.org/what-causes-li….

English
478
233
3.5K
1.2M
Debesh Mandal
Debesh Mandal@debesh·
"Peptides" feel like a fad just like any health fad. But hopefully bringing awareness to personalized medicine and inviting non-bio folks into the field will result in a net positive, fad aside
English
0
0
0
54
Chris Hayduk
Chris Hayduk@ChrisHayduk·
This is a great point, but I think it goes even beyond data availability! Text has a structural advantage because the data and tasks all exist in the same space - all you have to do is tokenize text, and you get everything! Whereas for bio, the data and the tasks live in different spaces. How do you jointly learn a protein sequence representation along with its structure, evolutionary fitness, signaling pathway involvement, etc etc? These are really difficult problems that change the structural assumptions made by transformers in text modeling tasks! The precise reason we got "Language Models are Few-Shot Learners" is that language models have already been trained on examples of the tasks we care about, since those examples exist in the data!
Debesh Mandal@debesh

unfathomable how much bio data will be required to match LLM performance in coding/text even if it was readily available. huge opportunity here

English
9
9
84
8.5K
Debesh Mandal
Debesh Mandal@debesh·
TTOs should have an agent (all UK universities should use the same one) that assesses a deal, categorises the spin-out terms and autogenerates all necessary documentation on day 1. Scope for negotiation should not exist and terms should be good enough to accept on the spot
English
0
0
0
13
Debesh Mandal
Debesh Mandal@debesh·
@PpeterPeter I drive past this a lot, it's great to see from the road and the double crescent is a nice touch
English
0
0
1
97
Peter barber
Peter barber@PpeterPeter·
a double crescent street we made in north London
Peter barber tweet media
English
103
100
2.1K
135.9K
Debesh Mandal
Debesh Mandal@debesh·
OpenAI have realised that Claude and ChatGPT are basically the same so they are now buying attention (TBPN, OpenClaw)
English
0
0
0
61
Debesh Mandal
Debesh Mandal@debesh·
@GeneInvesting I just saw MagicRNA's ph1 from September last year. Multiple doses, well tolerated in vivo CAR-T via LNP. Incredible compared to recent viral data, expecting Capstan later this year
English
0
0
1
39
Debesh Mandal
Debesh Mandal@debesh·
$NTLA now showing that in vivo editing with LNPs is safe and effective. Soon they will show it is commercially viable (moreso that ex vivo for sure). Then the in vivo CAR-T crowd will roll through and show the same in vivo cell therapies
English
1
0
3
439
Debesh Mandal retweetledi
Mushtaq Bilal, PhD
Mushtaq Bilal, PhD@MushtaqBilalPhD·
The growing inaccessibility of science that you can understand by paying €27.99
Mushtaq Bilal, PhD tweet media
English
132
2.3K
13.5K
278.8K
Persimmon Tree Investments
Persimmon Tree Investments@PersimmonTI·
$XBI Another Manic Monday Morning: $NTLA — Topline Data from Global Phase 3 HAELO Clinical Trial of Lonvoguran Ziclumeran in Hereditary Angioedema — 8:00AM. $CMPX — Topline Secondary Endpoints from the Phase 2/3 COMPANION-002 Study of Tovecimig in Biliary Tract Cancer — 8:00AM. $ORKA — Week 16 Data for ORKA-001 from the Ongoing EVERLAST-A Trial — 8:00AM.
Persimmon Tree Investments tweet mediaPersimmon Tree Investments tweet mediaPersimmon Tree Investments tweet mediaPersimmon Tree Investments tweet media
English
6
8
57
28K